Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough programs on its hands.

Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the ...

Moderna will offer free COVID-19 vaccines for "uninsured or underinsured people," the company announced Wednesday, pledging to ensure continued access to the shots after the public health ...

Moderna’s expected 400% hike for its COVID vaccine sparked outrage on Capitol Hill. The pharmaceutical giant could raise the price of the vaccine from its current $26 per dose to between $110 ...

The Moderna vaccine, the only product that the company has made which has proven a commercial success, has transformed Bancel into a billionaire. His net worth is now estimated at $5.3 billion.